Smith+Nephew 1st to Market with Revision Knee Indication on Robotics Platform

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the first cases for revision knee replacement utilizing its CORI◊ Surgical System.

Smith+Nephew First To Market With Revision Knee Indication On Robotics Platform

Dr. Thorsten Seyler of Duke University performed the first cases on August 17, 2022, combining Smith+Nephew’s handheld robotics technology with its LEGION◊ Revision Knee System. Smith+Nephew is the first orthopaedics company to receive FDA 510(k) clearance for a revision indication using a robotics-assisted platform.

RI.KNEE ROBOTICS utilizes image-free smart mapping, eliminating the need for pre-operative CT/MRI scans and the potential for image distortion due to in situ components from the primary procedure. Instead, surgeons are able to build patient-specific 3D models of the joint, register anatomy and bony defects after implant extraction, intra-operatively gap balance in real-time, and accurately precision mill for final placement of components.1-4

“The ability to visualize and create symmetric and balanced flexion and extension gaps with the CORI handheld robotic system has made one of the most challenging tasks in revision TKA an easier undertaking. I have never used more posterior stabilized over constrained bearings in a revision scenario. Additionally, the image-free system also allows for accurate mapping of bone defects after implant removal and enables surgeons to use a bone preserving approach to revision TKA,” said Dr. Seyler.

Revision knee surgery using robotics expands opportunity for health care professionals

Surgeons can now experience the power and versatility of one robotics platform when using the CORI Surgical System. With broader capabilities and expanded indications, it can address robotic-assisted total, partial, and now revision knee arthroplasty, along with computer-guided total hip arthroplasty. By coupling robotics with Smith+Nephew’s clinically-proven LEGION RK System with OXINIUM◊ Technology5*, surgeons can experience a truly comprehensive implant and technology portfolio.

“Being first to market with a revision indication for robotic-assisted knee replacement surgery is a significant milestone in orthopaedics,” said Randy Kilburn, Executive Vice President & General Manager, Orthopaedic Reconstruction, Robotics and Digital for Smith+Nephew. “Our ability to offer a robotic-assisted solution for partial, total, and now revision knee arthroplasty using a single platform is a true differentiator, especially when it potentially simplifies a complex procedure and maximizes the system’s capabilities for surgeons to restore patient lives and live Life Unlimited.”

Over the last six months, Smith+Nephew has launched RI.HIP NAVIGATION, RI.HIP MODELER, “Cementless” CONCELOC◊ Advanced Porous Titanium 3D printing technology with LEGION◊ CONCELOC Cementless Total Knee System, and now a revision knee indication. All are supported by the CORI◊ Surgical System.

More here.

References

  1. Bollars P, Boeckxstaens A, Mievis J, Janssen D. The Learning Curve and Alignment Assessment of an Image-Free Handheld Robot in TKA: The First Patient Series in Europe. Poster presented at: 19th Annual Meeting of the International Society for Computer Assisted Orthopaedic Surgery2019; New York, USA.
  2. Kopjar B, Schwarzkopf R, Chow J, et al. NAVIO Robotic Assisted Surgical System for Total Knee Arthroplasty Using JOURNEY II Guided-Motion Total Knee System. Poster presented at: ISTA 2-5 October, 2019; Toronto, Canada.
  3. Geller JA, Rossington A, Mitra R, Jaramaz B, Khare R, Netravali NA. Rate of learning curve and alignment accuracy of an image-free handheld robot for total Knee Arthroplasty. European Knee Society Arthroplasty Conference;2019; Valencia, Spain.
  4. Kaper BP, Villa A. Accuracy and Precision of a Handheld Robotic-guided Distal Femoral Osteotomy in Robotic-assisted Total Knee Arthroplasty. European Knee Society Arthroplasty Conference;2019; Valencia, Spain
  5. National Joint Registry for England, Wales and Northern Ireland: LEGION Revision OXINIUM (with Revision Tibial) implant summary report. 17 August 2022.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”